Novartis modifies GIPAP with immediate effect
NOVARTIS announced that the Glivec International Patient Assistance Program (GIPAP) has been modified to begin accepting new patients immediately, including patients that have been enrolled in generic imatinib patient assistance programmes.

Ranbaxy granted first USFDA approval for Ceflaclor tablets
Ranbaxy Laboratories Limited (Ranbaxy), announced that the company has received the first approval from the US Food and Drug Administration to market the anti-infective Cefaclor tablets, chewable, in 125 mg, 187 mg, 250 mg and 375 mg strengths.

NPIL buys-out partner’s 50 pc stake in Sarabhai for Rs 693 million
Nicholas Piramal India Limited (NPIL) has announced the buy-out of its partner’s 50 per cent stake in Sarabhai Piramal Pharmaceuticals Private Limited (SPPL) for Rs 693 million.

Strides net profit at Rs 6.32 crores, sales at Rs 275.90 crores
STRIDES Arcolab has reported a net profit of Rs 6.32 crores and sales of Rs 275.90 crores for the 18 month period ended September 2003, according to a press release issued by the company.